KALA BIO Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Randomized 87 patients to date in Phase 2b CHASE trial of KPI-012 in Persistent Corneal Epithelial Defect (PCED) ---- Continuing enrollment ...
BioRestorative Therapies Reports 2024 Financial Results and Provides Business Update
MELVILLE, N.Y., March 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem ...